JP2009527505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009527505A5 JP2009527505A5 JP2008555579A JP2008555579A JP2009527505A5 JP 2009527505 A5 JP2009527505 A5 JP 2009527505A5 JP 2008555579 A JP2008555579 A JP 2008555579A JP 2008555579 A JP2008555579 A JP 2008555579A JP 2009527505 A5 JP2009527505 A5 JP 2009527505A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- mixture
- weight
- copolymer
- doxorubicin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 39
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 20
- 229920001577 copolymer Polymers 0.000 claims 11
- 229960004679 doxorubicin Drugs 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 7
- 229920001400 block copolymer Polymers 0.000 claims 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 4
- 239000012736 aqueous medium Substances 0.000 claims 4
- 239000008101 lactose Substances 0.000 claims 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 3
- 229920001480 hydrophilic copolymer Polymers 0.000 claims 3
- 230000002209 hydrophobic effect Effects 0.000 claims 3
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims 3
- 238000000034 method Methods 0.000 claims 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 2
- 229960002216 methylparaben Drugs 0.000 claims 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229920001600 hydrophobic polymer Polymers 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000006353 oxyethylene group Chemical group 0.000 claims 1
- -1 polyoxypropylene copolymers Polymers 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/359,352 US8148338B2 (en) | 2006-02-22 | 2006-02-22 | Doxorubicin formulations for anti-cancer use |
| US11/359,352 | 2006-02-22 | ||
| PCT/CA2007/000182 WO2007095722A1 (en) | 2006-02-22 | 2007-02-08 | Doxorubicin formulations for anti-cancer use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009527505A JP2009527505A (ja) | 2009-07-30 |
| JP2009527505A5 true JP2009527505A5 (https=) | 2010-03-25 |
| JP5449784B2 JP5449784B2 (ja) | 2014-03-19 |
Family
ID=38428501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008555579A Expired - Fee Related JP5449784B2 (ja) | 2006-02-22 | 2007-02-08 | 抗癌用途のためのドキソルビシン製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8148338B2 (https=) |
| EP (1) | EP1991239B1 (https=) |
| JP (1) | JP5449784B2 (https=) |
| KR (1) | KR101074430B1 (https=) |
| CN (1) | CN101389343B (https=) |
| CA (1) | CA2640997C (https=) |
| WO (1) | WO2007095722A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8314151B2 (en) | 2008-04-29 | 2012-11-20 | Enzo Therapeutics, Inc. | Sphingosine kinase type 1 inhibitors, and processes for using same |
| US8372888B2 (en) * | 2008-04-29 | 2013-02-12 | Enzo Therapeutics, Inc. | Sphingosine kinase type 1 inhibitors, compositions and processes for using same |
| US20130150311A1 (en) * | 2011-12-13 | 2013-06-13 | Grzegorz Pietrzynski | Mixed poloxamer excipients |
| US8912215B2 (en) * | 2011-12-13 | 2014-12-16 | Everon Biosciences, Inc. | Rapamycin composition |
| EP2716291B1 (en) * | 2012-10-08 | 2019-11-27 | Universität Ulm | Combination of opioids and anticancer drugs for cancer treatment |
| EP3068364B1 (en) * | 2013-11-14 | 2021-11-03 | Metro Biotech NSW Pty Ltd | Nad+ precursor selected from nmn, naad, namn, or a pharmaceutically acceptable salt thereof, for use in treating a side effect of chemotherapy and/or radiotherapy in a subject |
| JP6875285B2 (ja) | 2015-03-13 | 2021-05-19 | コーニング インコーポレイテッド | エッジ強度試験方法および装置 |
| CA2984379C (en) | 2015-04-28 | 2024-06-11 | Newsouth Innovations Pty Limited | Targeting nad+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies, and inactivity |
| WO2018237379A2 (en) | 2017-06-23 | 2018-12-27 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| US10660879B2 (en) | 2017-06-23 | 2020-05-26 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| US20250295771A1 (en) | 2022-05-11 | 2025-09-25 | Celgene Corporation | Methods and uses related to t cell therapy and production of same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8426672D0 (en) * | 1984-10-22 | 1984-11-28 | Erba Farmitalia | Pharmaceutical compositions |
| US4927571A (en) * | 1987-05-18 | 1990-05-22 | Liposome Technology, Inc. | Preparation of injectable doxorubicin/liposome suspension |
| US6277410B1 (en) | 1992-10-08 | 2001-08-21 | Supratek Pharma Inc. | Copolymer compositions for oral delivery |
| US5817321A (en) * | 1992-10-08 | 1998-10-06 | Supratek Pharma, Inc. | Biological agent compositions |
| US6060518A (en) * | 1996-08-16 | 2000-05-09 | Supratek Pharma Inc. | Polymer compositions for chemotherapy and methods of treatment using the same |
| US20030157082A1 (en) * | 2002-01-31 | 2003-08-21 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 molecules |
| JP2004010479A (ja) * | 2002-06-03 | 2004-01-15 | Japan Science & Technology Corp | ブロック共重合体とアンスラサイクリン系抗癌剤を含む新規固型製剤及びその製造法 |
| GB0312309D0 (en) * | 2003-05-29 | 2003-07-02 | Gaslini Children S Hospital G | Targeted liposome |
-
2006
- 2006-02-22 US US11/359,352 patent/US8148338B2/en not_active Expired - Fee Related
-
2007
- 2007-02-08 CN CN2007800064317A patent/CN101389343B/zh not_active Expired - Fee Related
- 2007-02-08 JP JP2008555579A patent/JP5449784B2/ja not_active Expired - Fee Related
- 2007-02-08 KR KR1020087023127A patent/KR101074430B1/ko not_active Expired - Fee Related
- 2007-02-08 EP EP07701771.3A patent/EP1991239B1/en active Active
- 2007-02-08 CA CA2640997A patent/CA2640997C/en active Active
- 2007-02-08 WO PCT/CA2007/000182 patent/WO2007095722A1/en not_active Ceased